APRE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways...

Stats
Today's Volume	5 187.00
Average Volume	30 095.00
Market Cap	25.90M
EPS	$0 ( 2024-05-20 )
Next earnings date	( $-0.780 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.450
ATR14	$0.0840 (1.79%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Mirza Nadeem Q.	Buy	26 920	Stock Options (Right to Purchase)
2024-05-01	Mirza Nadeem Q.	Buy	6 730	Common Stock
2024-05-01	Mirza Nadeem Q.	Sell	2 250	Stock Option (Right to Buy)
2024-03-28	Hamill John P.	Buy	3 365	Common Stock
2024-03-28	Hamill John P.	Buy	13 460	Stock Options (Right to Buy)

INSIDER POWER
90.80
Last 96 transactions
Buy: 13 035 524 \| Sell: 1 176 966

Aprea Therapeutics Inc Correlation

10 Most Positive Correlations
OZEM	1
ORMP	0.867
VTRS	0.811
RFIL	0.809

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aprea Therapeutics Inc Financials

Annual	2023
Revenue:	$583 231
Gross Profit:	$576 178 (98.79 %)
EPS:	$-3.95

FY	2023
Revenue:	$583 231
Gross Profit:	$576 178 (98.79 %)
EPS:	$-3.95

FY	2022
Revenue:	$0
Gross Profit:	$-186 445 (0.00 %)
EPS:	$-2 714.18

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.740

Financial Reports:

No articles found.

Aprea Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.